The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Mutual Fund
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SBI Mutual Fund, through its various schemes, has bought a net 3.34 crore shares of Biocon, taking its total holding from 5.34% to 7.04% of the company's paid-up capital. The acquisition happened on January 16, 2026, through a mix of market purchase and Qualified Institutional Placement (QIP). SBI MF is not part of the promoter group. The previous disclosure under the same regulation was made in November 2025 when its holding stood at 5.00%. Biocon's total equity share capital also increased from ₹754 crore to ₹810 crore during this period, indicating fresh share issuance to institutional investors.
This is a significant institutional buying signal, with a large domestic fund increasing its stake by over 2 percentage points in just two months. The continued accumulation by SBI MF along with the QIP-based capital raise suggests strong institutional confidence in Biocon, which is generally positive for stock sentiment. Existing shareholders should note that promoter holdings are not impacted as SBI MF is a non-promoter institutional investor.